Allogeneic Hematopoietic Cell Transplantation clinical trials at UCLA

4 in progress, 1 open to eligible people

Showing trials for

  • Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

    open to eligible people ages 18-75

    This is a multi-center, randomized, double-blinded, placebo controlled trial.

    Los Angeles, California and other locations

  • Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.

    Los Angeles, California and other locations

  • Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies. This posting represents the Phase III component of Precision-T. The Precision-T Ph1b component is described under NCT04013685.

    Los Angeles, California and other locations

  • Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

    Los Angeles, California and other locations

Last updated: